Edition:
United Kingdom

People: Biohaven Pharmaceutical Holding Company Ltd (BHVN.N)

BHVN.N on New York Stock Exchange

61.70USD
20 May 2019
Change (% chg)

$-0.11 (-0.18%)
Prev Close
$61.81
Open
$60.81
Day's High
$63.24
Day's Low
$60.81
Volume
115,200
Avg. Vol
132,951
52-wk High
$65.55
52-wk Low
$29.17

Engelhart, James 

Mr. James Engelhart serves as Chief Financial Officer of Biohaven Pharmaceutical Holding Company Limited. Prior to this, from August 2014 to May 2016, he served as executive director of finance, Americas for Alexion Pharmaceuticals, Inc., and from March 2006 to July 2014, he served as a finance director for Energizer Holdings, Inc. From May 1998 to March 2006, Mr. Engelhart served in increasingly senior finance roles for BMS and held finance roles in R&D Operations and International Operations at Schering-Plough from 1992 to 1998. Mr. Engelhart started his career as an auditor with Coopers & Lybrand LLP from 1986 through 1991. Mr. Engelhart received his B.S. in accounting from Villanova University and is a CPA (inactive).

Basic Compensation

Total Annual Compensation, USD 2,497,200
Restricted Stock Award, USD --
Long-Term Incentive Plans, USD --
All Other, USD 13,080
Fiscal Year Total, USD 2,510,280

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Declan Doogan

247,770

Vlad Coric

3,855,660

James Engelhart

2,510,280

Charles Conway

1,626,150

Kimberly Gentile

--

Robert Berman

521,060
As Of  31 Dec 2017